Arcadia Biosciences (NASDAQ:RKDA) Issues Quarterly Earnings Results, Beats Estimates By $0.18 EPS

Arcadia Biosciences (NASDAQ:RKDA) announced its quarterly earnings data on Thursday. The basic materials company reported ($0.38) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.18, Zacks reports. The firm had revenue of $1.44 million during the quarter, compared to the consensus estimate of $1.90 million. Arcadia Biosciences had a negative net margin of 195.94% and a negative return on equity of 113.73%.

Arcadia Biosciences Stock Performance

NASDAQ RKDA traded up $0.06 during trading hours on Friday, hitting $0.63. 120,122 shares of the company’s stock were exchanged, compared to its average volume of 1,274,131. The business’s 50 day moving average is $0.73 and its 200-day moving average is $1.21. Arcadia Biosciences has a 12-month low of $0.50 and a 12-month high of $6.71. The firm has a market capitalization of $1.51 million, a P/E ratio of -0.11 and a beta of 0.56.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings cut Arcadia Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

About Arcadia Biosciences

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.